Archive | Kenya

RSS feed for this section

Defeating malaria through pharmaceutical systems strengthening

SIAPS has received funding from the US President’s Malaria Initiative (PMI) to work in eight countries—Angola, Burundi, Democratic Republic of the Congo (DRC), Ethiopia, Kenya, Guinea, Mali, and South Sudan—to strengthen pharmaceutical systems for improved malaria control. This report synthesizes the pharmaceutical systems strengthening efforts of SIAPS and documents how the approach was used to support efforts to control malaria.

Read full story · Comments are closed

Defeating malaria through pharmaceutical systems strengthening: A review of SIAPS’s activities in eight countries

SIAPS recently published the results of its activities in eight countries (Angola, Burundi, the Democratic Republic of the Congo (DRC), Ethiopia, Kenya, Guinea, Mali, and South Sudan) to control malaria. This report summarizes systems strengthening interventions that support the prevention and treatment of malaria. With funding from the US President’s Malaria Initiative (PMI) and based […]

Read full story · Comments { 0 }

Implementing QuanTB to Improve Forecasting, Supply Planning, and Early Warning Systems for TB Medicines: Kenya Report

SIAPS conducted an evaluation of its TB technical assistance and the QuanTB implementation in Kenya. Specific objectives were to determine:

  • Key achievements or results of the SIAPS QuanTB technical assistance in Kenya
  • Experiences and perspectives of the beneficiaries of the NTLD-P
  • Challenges and lessons learned

This report summarizes key aspects and results of the analysis for Kenya.

Read full story · Comments are closed

The Economic Cost of Non-adherence to TB Medicines Resulting from Stock-outs and Loss to Follow-up in Kenya – Research Summary

One of the key elements of successful tuberculosis (TB) control programs is adherence to treatment, which is a cornerstone of most international and national policies and guidelines. Non-adherence results in increased length and severity of illness, death, disease transmission, and drug resistance. Treatment interruption is often due to patient-related factors—classed as loss to follow-up (LTFU)—but can also be a result of provider issues, such as stock-outs of medicines. The purpose of this study was to estimate the morbidity, mortality, and economic impact of TB treatment interruption due to stock-outs and LTFU. The results are expected to help promote the benefits of ensuring the availability of good quality medicines and of undertaking interventions to reduce LTFU.

For the full report, please follow this link.

Read full story · Comments are closed

The Economic Cost of Non-adherence to TB Medicines Resulting from Stock-outs and Loss to Follow-up in Kenya

One of the key elements of successful tuberculosis (TB) control programs is adherence to treatment, which is a cornerstone of most international and national policies and guidelines. Non-adherence results in increased length and severity of illness, death, disease transmission, and drug resistance. Treatment interruption is often due to patient-related factors—classed as loss to follow-up (LTFU)—but can also be a result of provider issues, such as stock-outs of medicines. The purpose of this study was to estimate the morbidity, mortality, and economic impact of TB treatment interruption due to stock-outs and LTFU. The results are expected to help promote the benefits of ensuring the availability of good quality medicines and of undertaking interventions to reduce LTFU.

For the research summary, please follow this link.

Read full story · Comments are closed